arsenic trioxide has been researched along with Gallbladder Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, Z; Liu, H; Lv, C; Pan, H; Suo, T; Tong, S; Wang, Y | 1 |
| Ai, Z; Lu, W; Qin, X | 1 |
| Ai, Z; Liu, H; Lu, W; Qin, X; Shen, Z; Sou, T; Ton, S | 1 |
| He, Z; Qian, J; Qin, S | 1 |
4 other study(ies) available for arsenic trioxide and Gallbladder Neoplasms
| Article | Year |
|---|---|
Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Glycoproteins; Humans; Neoplastic Stem Cells; Oxides; Peptides; Plasmids; Proto-Oncogene Proteins c-akt; RNA, Messenger; Signal Transduction; Transfection | 2011 |
Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Down-Regulation; Gallbladder Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor.
Topics: Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cyclin D1; Down-Regulation; Gallbladder Neoplasms; Humans; Oxides; Sp1 Transcription Factor; Transcription, Genetic; Transfection | 2007 |
[Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gallbladder Neoplasms; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxides; Quality of Life; Treatment Outcome | 2001 |